Melanoma
Conditions
Keywords
melanoma, vaccine, IL2 low dose
Brief summary
This study is an open-label, pilot study of an autologous tumor cell vaccine.
Detailed description
Regimen: A vaccine comprising autologous melanoma cells plus GM-CSF in-adjuvant will be administered intradermally at a single dose. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods.
Interventions
BIOLOGICALautologous tumor cells plus GM-CSF-in Adjuvant
Autologous tumor cells plus 225 ug GM-CSF in-adjuvant: The autologous tumor cells will be administered intradermally. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods.
Sponsors
Craig L Slingluff, Jr
Study design
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patients who have been diagnosed, by cytologic or histologic examination, with stage III or stage IV melanoma, where sufficient resected tumor is available for vaccine preparation (approximately 3 g tumor). * Measurable tumor after resection is not required. * Patients with up to 3 brain metastases may be included if the metastases are all \< 2 cm in diameter, are asymptomatic, and there is no mass effect or they have been treated successfully by surgical excision or by gamma knife radiation therapy. * Patients who have had a larger number of brain metastases resected or treated and resolved after gamma knife radiation therapy may be included if their status at the time of study initiation meets these criteria. * For those patients with resected melanoma, surgical resections must have been performed within 6 months prior to entry. All patients must have: * ECOG performance status 0-1, and, ability and willingness to give informed consent. * Laboratory parameters as follows: ANC \> 1000/mm3, and Platelets \> 100,000 and Hgb \> 10. * Hepatic: AST and ALT up to 1.5 x upper limits of normal (ULN), Bilirubin within ULN, Alkaline phosphatase up to 1.5 x ULN * Renal: Creatinine within ULN * Serology: HIV negative, Hepatitis C virus-negative. * Patients who are not candidates for interferon, for people who decide not to take interferon, or for people who have failed interferon therapy (those patients who have progressed while on interferon therapy or who experienced a major toxicity while receiving treatment).
Exclusion criteria
* Patients who are currently receiving cytotoxic chemotherapy or radiation therapy, or who have received that therapy within the preceding 4 weeks. * Patients who are currently receiving investigational agents, or who have received investigational agents within the preceding 30 days. * Patients with known or suspected allergies to any component of the vaccine. * Patients receiving the following medications at study entry or within 30 days are excluded: * Allergy desensitization injections * Corticosteroids, administered parenterally or orally. * Topical corticosteroids are acceptable, Any growth factors, Interferons, Interleukin 2 (IL-2). * Prior melanoma vaccinations will not be an
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cytotoxic T-cell response to autologous tumor (as measured by staining assay) | — |
Secondary
| Measure | Time frame |
|---|---|
| Cytotoxic T-cell response to defined melanoma antigens. 1: Activation antigen expression by lymph node T-cells 2: Delayed-type hypersensitivity response to autologous tumor cells. 3: Antibody response to autologous tumor cells. | — |
Countries
United States
Outcome results
None listed